NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization262.02 mln
Float86.31 mln
Earnings Date07/30/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-3.52
Highly reliable
1-Year Forecast
3.10
Attractive
Relative Strength
16
/ 100
Significantly lagging
Debt / Equity
1.18
Elevated leverage
ROE
-188
Deeply negative
Business Description
Alector is a US-based clinical-stage biotech company focused on developing treatments that slow or stop diseases that cause the brain to deteriorate over time. Its portfolio includes several drug candidates targeting Alzheimer's, Parkinson's, and related conditions, spanning both clinical and early research stages. The company works alongside GlaxoSmithKline to advance a shared set of treatments aimed at restoring key proteins involved in brain health. Founded in 2013 and based in South San Francisco, Alector continues to build on its science-driven approach to fighting neurological disease.
